- Rare complications post intravesical application of Bacillus-Calmette Guérin (BGG) vaccine2023 | Third Faculty of Medicine
- 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-192021 | Second Faculty of Medicine
- What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence2018 | Second Faculty of Medicine
- Ten Years' Experience with the Discontinuation of the Bacillus Calmette-Guérin Vaccination in the Czech Republic2021 | First Faculty of Medicine, Second Faculty of Medicine
- Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy2023 | Second Faculty of Medicine
- Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients2015 | First Faculty of Medicine, Second Faculty of Medicine
- Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial2023 | Second Faculty of Medicine
- Does non-specific immunotherapy have a place in modern oncology treatment?2019 | First Faculty of Medicine
- Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study2024 | Second Faculty of Medicine
- Unanswered Questions for Bladder Tumours Unresponsive to Bacillus Calmette-Guerin2020 | Second Faculty of Medicine
- Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Non-muscle-invasive Bladder Cancer2012 | Second Faculty of Medicine
- T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues2018 | Second Faculty of Medicine
- Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer2021 | Second Faculty of Medicine
- Re: The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin2015 | Second Faculty of Medicine
- The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin2016 | First Faculty of Medicine, Second Faculty of Medicine
- Photodynamic diagnosis /PDD/ and urinary cytology in monitoring the results of intravesical bacillus Calmette-Guerin /BCG/ treatment of superficial bladder carcinomaPublication without faculty affiliation
- Methylation status as a predictor of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor2017 | Faculty of Medicine in Hradec Králové
- Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Bohle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-612017 | Second Faculty of Medicine
- Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS"2020 | Second Faculty of Medicine
- Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)2005 | Third Faculty of Medicine
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update2019 | First Faculty of Medicine, Second Faculty of Medicine
- Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies2021 | Second Faculty of Medicine
- Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group2022 | Second Faculty of Medicine
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy2016 | Second Faculty of Medicine
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy2018 | Second Faculty of Medicine
- BCG - history, method principe, indication, effectivity, dosage2019 | Faculty of Medicine in Hradec Králové
- Granulomatous pulmonary involvement in a female patient with common variable immunodeficiency2009 | First Faculty of Medicine
- What is the Optimal Treatment Strategy for T1 Bladder Tumors?2010 | Second Faculty of Medicine
- Principles and Challenges in anti-COVID-19 Vaccine Development2021 | Second Faculty of Medicine
- Complications of BCG intravesical therapy - BCGitis2019 | Faculty of Medicine in Hradec Králové